View all data FOR FREE!
Create an account today, no credit card required.
| Issue Type | XXXX |
|---|---|
| Country | Belgium |
| Industry | XXXX |
| Region | XXXX |
| Maturity Date | 2030-03-20 |
| Par Value | 100000 |
| Callable | XXXX |
| Next Call Date | XXXX |
| Call Type | XXXX |
| Call Price (%) | XXXX |
| Series | XXXX |
| Class | XXXX |
| Maturity Structure | XXXX |
| Amount Outstanding (mil) | 500.00 |
| Coupon | 4.25 |
|---|---|
| Coupon Type | XXXX |
| Coupon Frequency | XXXX |
| First Coupon Date | XXXX |
| Last Coupon Date | XXXX |
| Sinking Fund | XXXX |
|---|---|
| Security | XXXX |
| Subordination | XXXX |
| Debt Type | XXXX |
| Issue Date | XXXX |
|---|---|
| Dated Date | XXXX |
| Issue Size (mil) | 500 |
| Min. Piece | XXXX |
| Min. Increment | XXXX |
This UCB SA corporate medium term notes has a 4.25% fixed rate coupon paid on a annual basis. It was issued on March 20, 2024 with an issue size of 500.00 million EUR and matures on March 20, 2030 with a last coupon date of March 20, 2029. |
UCB SA, founded in 1928 and headquartered in Brussels, Belgium, is a global biopharmaceutical company focused on the discovery and development of innovative medicines for severe diseases, particularly in neurology and immunology. The company specializes in therapies for conditions such as epilepsy, multiple sclerosis, and Crohn's disease, positioning itself as a key player in the pharmaceutical industry.